Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.44 |
| ▸ | LAP3 | P28838 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 4/20 | 0.39 |
| ▸ | PPARA | Q07869 | 4/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13535118 | 0.87 | LTA4H (0.49) | LTA4HLAP3ITGB3ITGA2BALDH1A1 | |
| SCHEMBL14728209 | 0.83 | PREP (0.39) | ITGB3ITGA2BPREPADRB3ATM | |
| SCHEMBL14728212 | 0.83 | LDHA (0.44) | ITGB3ITGA2BPPARGPPARAPREP | |
| SCHEMBL13535121 | 0.83 | EPOR (0.44) | LTA4HLAP3ITGB3ITGA2BBTN3A1 | |
| SCHEMBL13535725 | 0.81 | ITGB3 (0.45) | LTA4HLAP3ITGB3ITGA2B | |
| SCHEMBL23501187 | 0.81 | ALDH1A1 (0.60) | ALDH1A1TSHRADRB2ADRB1ADRB3 | |
| SCHEMBL1701856 | 0.81 | ITGB3 (0.67) | ITGB3ITGA2BALDH1A1CTSB | |
| SCHEMBL12052784 | 0.81 | ITGB3 (0.67) | ITGB3ITGA2BALDH1A1CTSB | |
| SCHEMBL305427 | 0.79 | TDP1 (0.50) | ALDH1A1FFAR1FFAR4 | |
| SCHEMBL3907320 | 0.79 | PRKCA (0.42) | ALDH1A1BTN3A1PREPADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230131121-A1 | BRANCHED DISCRETE PEG CONSTRUCTS | AUDAX PRIVATE DEBT LLC, AS AGENT | 2023-04-27 | — | — | US | disclosed |
| US-20230131121-A1 | BRANCHED DISCRETE PEG CONSTRUCTS | AUDAX PRIVATE DEBT LLC, AS AGENT | 2023-04-27 | — | — | US | disclosed |
| EP-2750681-B1 | BRANCHED DISCRETE PEG CONSTRUCTS | QUANTA BIODESIGN LTD (US) | 2020-05-27 | — | — | EP | disclosed |
| US-20170313656-A1 | Branched Discrete PEG Constructs | QUANTA BIODESIGN, LTD. | 2017-11-02 | — | — | US | disclosed |
| US-20150065711-A1 | Discrete PEG Constructs | EQUIP, LLC (US) | 2015-03-05 | — | — | US | disclosed |
| US-20130052130-A1 | Branched Discreet PEG Constructs | UNIVERSITY OF WASHINGTON (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313656-A1 | Branched Discrete PEG Constructs | BTD, IDUA, DNPEP | LTA4H 1024/4885LAP3 155/4885ITGB3 1193/4885 |
| US-20150065711-A1 | Discrete PEG Constructs | MUC1, EGFR, LNPEP | LTA4H 4033/4885LAP3 405/4885ITGB3 1886/4885 |
| US-20230131121-A1 | BRANCHED DISCRETE PEG CONSTRUCTS | BTD, IDUA, DNPEP | LTA4H 917/4885LAP3 154/4885ITGB3 1211/4885 |
| US-20130052130-A1 | Branched Discreet PEG Constructs | BTD, DNPEP, IDUA | LTA4H 1222/4885LAP3 151/4885ITGB3 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.